ASCLS eNewsBytes

• Nasal flu vaccine flumist gets FDA approval for at-home use October 8, 2024
  The FDA has approved the at-home use of FluMist, an influenza vaccine administered by nasal spray, for people aged 2 through 49. The vaccine, made by AstraZeneca, contains a weakened form of live influenza virus strains A and B and is sprayed into the nose.
• A data-driven approach to sequencing HIV vaccine immunogens October 8, 2024
  Researchers have been working on developing HIV vaccine immunogens that can stimulate the immune system to generate broadly neutralizing antibodies, which are crucial for effective vaccines. These antibodies are difficult to induce through vaccination due to their mutated nature.
• What is the deadly Marburg virus and where has it spread? October 8, 2024
  Rwanda is fighting its first outbreak of the highly virulent Marburg virus, with 11 people reported to have died. The virus, from the same family as Ebola, causes a haemorrhagic fever that can damage blood vessels and cause internal bleeding, which can be fatal.
• FDA now weighing approval of first new sunscreen ingredient in decades October 8, 2024
  European skincare company DSM-Firmenich is awaiting the FDA's approval of the first new sunscreen ingredient in decades, bemotrizinol, branded as PARSOL Shield. The FDA is expected to decide within the next 17.5 months, by March 2026, on the company's request to approve the sunscreen ingredient.
• Acute necrotizing encephalopathy caused by bacterial infection October 8, 2024
  Acute necrotizing encephalopathy is a viral infection primarily affecting children under 6 years old, characterized by rapid neurological deterioration. It often presents symptoms like coma, seizures or focal deficits without central nervous system infection. ANE is more than a simple CNS infection disease, with symmetric bilateral lesions in various brain regions.